Provenance Wealth Advisors’s Pacira BioSciences PCRX Stock Holding History

Provenance Wealth Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.81K	Hold	150	–	–	﹤0.01%	407
2026 Q1	$3.39K	Hold	150	–	–	﹤0.01%	358
2025 Q4	$3.88K	Hold	150	–	–	﹤0.01%	350
2025 Q3	$3.87K	Hold	150	–	–	﹤0.01%	365
2025 Q2	$3.58K	Hold	150	–	–	﹤0.01%	359
2025 Q1	$3.73K	Hold	150	–	–	﹤0.01%	367
2024 Q4	$2.83K	Hold	150	–	–	﹤0.01%	401
2024 Q3	$2.26K	Hold	150	–	–	﹤0.01%	449
2024 Q2	$4.29K	Hold	150	–	–	﹤0.01%	331
2024 Q1	$4.38K	Hold	150	–	–	﹤0.01%	360
2023 Q4	$5.06K	Hold	150	–	–	﹤0.01%	362
2023 Q3	$4.6K	Buy	+150	New	+$5.41K	﹤0.01%	275

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Provenance Wealth Advisors's PCRX Position: Q2 2026 in Review

Provenance Wealth Advisors held its Pacira BioSciences (PCRX) position steady in Q2 2026 at 150 shares worth $3.81K. The position accounts for ﹤0.01% of the portfolio, ranked #407.

Provenance Wealth Advisors first reported a position in PCRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $5.06K in Q4 2023. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Provenance Wealth Advisors held 150 shares of Pacira BioSciences worth $3.81K as of Q2 2026.
Provenance Wealth Advisors left its Pacira BioSciences share count unchanged in Q2 2026.
Pacira BioSciences made up ﹤0.01% of Provenance Wealth Advisors's portfolio in Q2 2026, its #407 holding.
Provenance Wealth Advisors first reported a position in Pacira BioSciences in Q3 2023 and has held it in 12 quarters since.
Provenance Wealth Advisors's Pacira BioSciences position peaked at $5.06K in Q4 2023.
254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Provenance Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.